Lista de obras - Paola Meraviglia - Dominio Público Uruguay

96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience

artículo científico publicado en 2012

Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients

artículo científico publicado en 2006

Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

article

Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

artículo científico publicado en 2011

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

artículo científico publicado en 2017

Clinical and histologic aspects of chronic delta hepatitis

artículo científico publicado en 1987

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

artículo científico publicado en 2011

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing

artículo científico publicado en 2012

Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study

artículo científico publicado en 2015

Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).

artículo científico publicado en 2007

Determinants of bone diseases in tenofovir-treated HIV patients.

artículo científico publicado en 2016

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

artículo científico publicado en 2016

Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF.

artículo científico publicado en 2017

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

artículo científico publicado en 2016

Eligibility and feasibility of the treatment of chronic hepatitis C in a Cohort of Italian HIV-positive patients at a single HIV reference center.

artículo científico publicado en 2011

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

artículo científico publicado en 2013

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

artículo científico publicado en 2013

HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users

artículo científico publicado en 2016

HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America ⬇️

artículo científico publicado en 2012

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications

artículo científico publicado en 2012

High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype

article

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

artículo científico publicado en 2011

Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

artículo científico publicado en 2010

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

artículo científico publicado en 2011

Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients

artículo científico publicado en 2012

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

artículo científico publicado en 2011

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience

artículo científico publicado en 2010

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

artículo científico publicado en 2004

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

artículo científico publicado en 2013

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial

artículo científico publicado en 2013

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

article

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

artículo científico publicado en 2015

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

artículo científico

Pandemic influenza vaccine in adult HIV-1-infected patients

article

Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics

artículo científico publicado en 2014

Post transfusion hepatitis: comparison between homologous and autologous blood transfusion

artículo científico publicado el 1 de mayo de 1992

Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

artículo científico publicado en 2006

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

artículo científico publicado en 2005

Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy

article

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

artículo científico publicado en 2009

Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index.

artículo científico publicado en 2002

Secondary hyperparathyroidism in HIV patients

article

Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women

artículo científico publicado en 2013

Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals

artículo científico publicado en 2011

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.

artículo científico publicado en 2011

Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.

artículo científico publicado en 2010

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

artículo científico publicado en 2003

When food can make the difference: The case of elvitegravir-based co-formulation

artículo científico publicado en 2016

cART Durability and Causes for Treatment Switching or Discontinuation in HIV-Positive Patients Older Than 50 Years of Age

article

Lista de obras de Paola Meraviglia

96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience

Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients

Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

Clinical and histologic aspects of chronic delta hepatitis

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing

Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study

Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).

Determinants of bone diseases in tenofovir-treated HIV patients.

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF.

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

Eligibility and feasibility of the treatment of chronic hepatitis C in a Cohort of Italian HIV-positive patients at a single HIV reference center.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users

HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America ⬇️

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications

High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

Pandemic influenza vaccine in adult HIV-1-infected patients

Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics

Post transfusion hepatitis: comparison between homologous and autologous blood transfusion

Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index.

Secondary hyperparathyroidism in HIV patients

Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women

Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.

Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

When food can make the difference: The case of elvitegravir-based co-formulation

cART Durability and Causes for Treatment Switching or Discontinuation in HIV-Positive Patients Older Than 50 Years of Age